Myelodysplastic Syndromes (MDS)

Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study

Secondary AML - Webinar 2025

Thumbnail for video Watch Now

Topic(s)
Acute Myeloid Leukemia (AML)
In this webinar, Drs. Fadi Haddad and Jayastu Senapati discuss the diagnosis secondary AML from MDS, treatment options available to patients and symptom management.

AAMDSIF Supports the Accelerating Kids' Access to Care Act

Original Publication Date
Article Source
Coalition Action
AAMDSIF Supports the Accelerating Kids' Access to Care Act. On March 26, 2025, AAMDSIF joined with 212 additional patient advocacy and medical center organizations in urging members of the US Congress to pass the Accelerating Kids’ Access to Care Act. Passage of this bill will…
Subscribe to Myelodysplastic Syndromes (MDS)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.